SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 1 — Theodore Roosevelt — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.
| Patient | Theodore Roosevelt |
|---|
| Date of birth | 1858-10-27 |
|---|
| Identifiers | MRN HR-NI012-SYN-TD; SSN (made up) 000-12-6157 |
|---|
| Document date | 1882-03-09 |
|---|
| Author | Amos Kettering, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Subjective
The patient attends this visit for primary care visit for frequent wheeze, night cough, and breathlessness during training. [S]
Objective
FEV1 before bronchodilator: 3.2 L (low); FEV1 percent predicted: 72% (low); FVC: 4.8 L; FEV1/FVC ratio: 0.67 (low); FEV1 after bronchodilator: 3.74 L; Asthma Control Test: 13; PHQ-2: 0. [S]
Vital Signs
| Date | Measure | Value | Unit | Provenance |
| 1882-03-09 | Body height | 175 | cm | S |
| 1882-03-09 | Body weight | 72 | kg | S |
| 1882-03-09 | Body mass index (BMI) [Ratio] | 23.5 | kg/m2 | S |
| 1882-03-09 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1882-03-09 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1882-03-09 | Heart rate | 84 | /min | S |
| 1882-03-09 | Respiratory rate | 18 | /min | S |
| 1882-03-09 | Body temperature | 36.8 | Cel | S |
| 1882-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 1882-03-09 | FEV1 --pre bronchodilation | 3.2 | L | >=3.65 L | Low | S |
| 1882-03-09 | FEV1 measured/predicted | 72 | % | >=80% | Low | S |
| 1882-03-09 | Forced vital capacity [Volume] Respiratory system | 4.8 | L | >=4.4 L | Normal | S |
| 1882-03-09 | FEV1/FVC | 0.67 | {ratio} | >=0.72 | Low | S |
| 1882-03-09 | FEV1 --post bronchodilation | 3.74 | L | >=3.65 L | Normal | S |
| 1882-03-09 | Total score [ACT] | 13 | {score} | | | S |
| 1882-03-09 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | | | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Albuterol 90 mcg/actuation inhaler, two inhalations as needed for wheeze (bought after an urgent care visit; used most days before intake) | Two inhalations every 4 hours as needed | Respiratory tract route | 1881-12-15 to 1882-03-09 | stopped | S |
| Budesonide-formoterol 160/4.5 mcg inhaler, two inhalations twice daily for maintenance | Two inhalations twice daily, with a spacer, rinsing the mouth afterwards | Respiratory tract route | 1882-03-09 | active | S |
| Budesonide-formoterol 160/4.5 mcg inhaler, one inhalation as needed for symptoms and before exercise; no more than 12 inhalations a day in total | One inhalation as needed, repeated after a few minutes if needed; maximum 12 inhalations a day including maintenance doses | Respiratory tract route | 1882-03-09 | active | S |
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Moderate persistent asthma, uncontrolled at intake, with reversible airflow obstruction on spirometry; synthetic modern diagnosis linked to his documented lifelong asthma | active | confirmed |
J45.40 | S — Synthetic modern classification confirmed by spirometry; the historical asthma is D and its persistence into adulthood is R. |
| Myopia, both eyes, corrected with glasses since boyhood | active | confirmed |
H52.13 | S — Synthetic modern entry linked to his documented near-sightedness. |
Assessment
- Moderate persistent asthma, uncontrolled at intake, with reversible airflow obstruction on spirometry; synthetic modern diagnosis linked to his documented lifelong asthma: active, confirmed [S]
- Myopia, both eyes, corrected with glasses since boyhood: active, confirmed [S]
Plan of Treatment
- Stop reliever-only albuterol and start budesonide-formoterol maintenance-and-reliever therapy at Step 4 (two inhalations twice daily plus one as needed, up to 12 a day), with a spacer and inhaler-technique teaching. Guideline: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020) [S]
- Written asthma action plan with symptom and peak-flow zones (green 80 percent or more of personal best, yellow 50 to 79 percent, red below 50 percent), reviewed at every visit and after every exacerbation. Guideline: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026) [S]
- Pulmonology referral to confirm the diagnosis, assess type 2 inflammation, and advise on exercise-induced symptoms, allergen measures, and treatment step. Guideline: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020) [S]
- Asthma Control Test, inhaler technique, adherence, reliever use, triggers, and exacerbation history at every visit; review one to three months after starting controller therapy, then every three to twelve months, and within one week of any exacerbation; spirometry at diagnosis, three to six months after stabilization, then every one to two years. Guideline: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026) [S]
- Explain that exercise improves fitness but does not treat airway inflammation; take one reliever inhalation before boxing or rowing; use dust-mite-impermeable bedding covers once sensitization is shown. Guideline: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020) [S]
- Yearly influenza vaccine, pneumococcal vaccination for chronic lung disease, and COVID-19 vaccination by CDC guidance. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026); Summary of Risk-based Pneumococcal Vaccination Recommendations (2025) [S]